Lululemon Flubbed Quarter, Founder: What Investors Need
Lululemon posted a mixed quarter: international sales led growth while the core US market softened. This analysis dig...
When To Revisit Your Budget Plan
Timely reviews keep plans relevant. This intro covers triggers and a simple process to revisit and revise your budget plan.
20,890 articles
Tesla's Solid Delivery Report Triggers Investor Reassessment
Tesla’s latest delivery numbers surprised many investors. Despite solid growth, the stock moved lower as analysts wei...
Nonfarm Payrolls and Confirmation Bias in Markets
The monthly nonfarm payrolls report is a big market event, but it can mislead if you lean on it without guarding agai...
This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Dragonfly (DFLI) 2026 Earnings Outlook and Insights
Explore dragonfly (dfli) 2026 earnings to understand growth drivers, margin discipline, and what the results imply fo...
U.S. Crude Storage Levels Fall: What Investors Should Do
As u.s. crude storage levels tighten toward a critical threshold, investors face a potentially powerful price signal....
Micron's Strategy Will Face SK Hynix and Samsung Capex
Micron's strategy will face a sweeping test as two giants in the memory market push forward with enormous spending. T...
Waze Co-Founder Levine Entrepreneurship: Real-World Lessons
Explore how Uri Levine’s problem-first approach fuels startup success, from Waze’s ascent to the future of autonomous...
Plug Power Stock Surging: Why the Jump Has Momentum
Plug Power stock surging momentum is turning heads after a February stumble. This article breaks down the catalysts, ...
Carnival Gets Iran War: Will Cruise Stocks Rebound in 2025?
Geopolitics can shake travel stocks fast. This article breaks down how Carnival, the world’s largest cruise operator,...
Strategy Capital Exits Monday.com: A Yearlong Selloff
A year-long selloff in monday.com highlights how a single large exit can ripple through stock prices, risk, and inves...
CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status